| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.1988.6.3.434 |
| P698 | PubMed publication ID | 3127550 |
| P50 | author | Dan Longo | Q12100062 |
| P2093 | author name string | R Williams | |
| A E Maluish | |||
| S A Sherwin | |||
| K Gordon | |||
| W J Urba | |||
| R G Steis | |||
| D Coggin | |||
| E R Crisp | |||
| W R Overton | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 434-445 | |
| P577 | publication date | 1988-03-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | The determination of an immunologically active dose of interferon-gamma in patients with melanoma | |
| P478 | volume | 6 |
| Q67752780 | A randomized prospective clinical trial to determine the efficacy of interferon-γ in severely injured patients |
| Q41206909 | Active vs. passive resistance, dose-response relationships, high dose chemotherapy, and resistance modulation: a hypothesis |
| Q45156441 | Acute hematologic effects of interferon alpha, interferon gamma, tumor necrosis factor alpha and interleukin 2. |
| Q70487785 | Antitumor response to recombinant murine interferon gamma correlates with enhanced immune function of organ-associated, but not recirculating cytolytic T lymphocytes and macrophages |
| Q40859819 | Autologous graft-versus-host disease: immunotherapy of breast cancer after bone marrow transplantation |
| Q36692582 | Biologic Agents and Approaches in the Management of Patients with Lymphoma: A Critical Appraisal |
| Q38015061 | Biological response modifiers in the management of patients with breast cancer |
| Q36589103 | Central Nervous System Toxicity of Biological Response Modifiers |
| Q67720631 | Clinical and biologic effects of combination therapy with gamma-interferon and tumor necrosis factor |
| Q34590873 | Cytokines, GM-CSF and IFNgamma administered by priming and post-chemotherapy cycling in recurrent ovarian cancer patients receiving carboplatin |
| Q36080426 | EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group |
| Q37912575 | Endogenous substances as drugs. Issues related to the application of cytokines in cancer therapy |
| Q68033713 | Enhanced serum levels of soluble HLA class I molecules are induced by treatment with recombinant interferon-gamma (IFN-gamma) |
| Q67700808 | Functional evaluation of tumor-infiltrating mononuclear cells. Detection of endogenous interferon-γ and tumor necrosis factor-α in human colorectal adenocarcinomas |
| Q74715597 | How does interferon work? Does it even matter? |
| Q45738176 | Immunoprophylactic strategies against respiratory influenza virus infection |
| Q67574213 | Increased expression of IgG Fc receptor type I on neutrophils and monocytes from HIV-infected subjects |
| Q50191533 | Increased intracellular killing of bacteria in vitro by monocytes of patients with metastatic melanoma before and during treatment with interferon-γ and interferon-α |
| Q58615655 | Induction of human B2 bradykinin receptor mRNA and membrane receptors by IFNγ |
| Q36621312 | Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial |
| Q38242687 | Interferon-gamma: a review |
| Q33492459 | Interferons combined with chemotherapy in the treatment of stage III-IV non-small cell lung cancer--a randomised study |
| Q44756331 | Keratinocyte growth factor-2 production in an ompT-deficient Escherichia coli K-12 mutant |
| Q35084330 | Malignant melanoma: current state of primary and adjuvant treatment |
| Q39271021 | Methods to improve adoptive T-cell therapy for melanoma: IFN-γ enhances anticancer responses of cell products for infusion |
| Q35817275 | Monocytes and polymorphonuclear neutrophils of patients with streptococcal pharyngitis express increased numbers of type I IgG Fc receptors |
| Q28359817 | N-formyl-methionyl-leucyl-phenylalanine inhibits both gamma interferon- and interleukin-10-induced expression of FcgammaRI on human monocytes |
| Q36636530 | New Therapeutic Modalities for Cancer |
| Q34612417 | Nonclinical evaluation of therapeutic cytokines: immunotoxicologic issues |
| Q73850407 | Pharmacodynamic aspects of peptide administration biological response modifiers |
| Q68345009 | Phase I/II study of recombinant interferon alpha and gamma in advanced progressive renal-cell carcinoma |
| Q54098958 | Reduction of tumorigenicity by an interferon-gamma-gene-transduced tumor on another syngeneic tumor in a murine model. |
| Q67677208 | Role of Interferons in the Thearpy of Melanoma |
| Q74202011 | Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC Lung Cancer Cooperative Group |
| Q36268672 | Synergy in the toxicity of cytokines: Preclinical studies |
| Q35544439 | The Role of IFN-γ in Surgical Patients |
Search more.